PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment

Get Permission

An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the Journal of Clinical Oncology. The tool, known as PREMMplus, assesses whether an individual is likely to carry a germline change in nearly 20 genes linked to cancer. People with a high probability score could then receive genetic testing to determine if they harbor such changes and could benefit from measures to prevent the cancer or detect it at the earliest possible stage.

The tool fills a clear need at a time when the field of cancer genetic risk and genetic counseling is undergoing rapid change, say the authors of the study.

“Today, we know of many more inherited genetic variations associated with cancer than we knew of just 10 years ago, and it’s now standard practice at many cancer centers to test patients and family members for these variations,” said the senior author of the study, Sapna Syngal, MD, MPH, of Dana-Farber and Brigham and Women’s Hospital. “It has become increasingly complex to determine which individuals warrant germline testing. At the same time, genetic counselors—who traditionally meet with people prior to testing—are in short supply.”

More About PREMMplus

PREMMplus asks users questions about their age, sex, ethnicity, and personal and family history of 18 cancers. It then calculates the probability that the person carries an inherited mutation in any of 19 genes associated with those cancers. The researchers recommend that people whose probability is 2.5% or greater be referred for testing to verify if they have that mutation.

The PREMMplus model was developed using data from 7,280 adults who underwent testing for hereditary cancer risk at Dana-Farber’s Genetics Program over a 15-year period. Genetic counselors interviewed each of the participants, collecting personal data and detailed family histories of cancer occurrences. By correlating the genetic testing results with information gathered by counselors, Dana-Farber data scientists produced an algorithm for predicting the likelihood that an individual has an inherited mutation in any of the 19 cancer-related genes.

Current Study

The current study tested PREMMplus’ predictive power in more than 30,000 people at Dana-Farber and California-based Ambry Genetics who had undergone germline testing for multiple cancer susceptibility genes. Researchers found it had high sensitivity: the vast majority of users predicted to have a specific germline change actually did have that change, as shown by genetic testing. Likewise, it had a high negative-predictive value: when users were predicted not to have specific germline changes, genetic testing found that they did not, in fact, have them.

“Our findings show that PREMMplus has the potential to change the model by which patients and family members are referred for genetic testing and counseling,” Dr. Syngal remarked. “Traditionally, if a physician or patient is concerned about a family history of cancer, the patient is referred to a genetics clinic, where a counselor takes a complete family history. PREMMplus can be directly embedded in a patient’s electronic medical record, and patients could fill out the questionnaire themselves. Based on the result, health-care providers can then determine who should receive genetic testing.”

He concluded: “At a time when there’s a shortage of genetic counselors, PREMMplus can help streamline risk assessment and ensure that their time can be focused on where they’re most needed—helping people understand the results of genetic testing and the options available when a cancer-susceptibility gene is found.”

Disclosure: Funding was provided by the National Institutes of Health. For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.